• Hani Babiker, MD, and patient

    Too Much of a Good Thing: Managing Immunotherapy Side Effects

    Immunotherapy can backfire when a supercharged immune system attacks healthy cells, but researchers are hopeful for the future.

  • Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

    Pancreatic Cancer Patients with BRCA Mutation May Benefit from Targeted Drug

    Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

  • Daruka Mahadevan, MD, PhD, and Eric Weterings, PhD

    Immunotherapy: Harnessing the Power of the Immune System

    Designer antibodies, such as checkpoint inhibitors, have revolutionized cancer treatment.

Hani Babiker, MD, and patient
Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.
Daruka Mahadevan, MD, PhD, and Eric Weterings, PhD
Hani Babiker, MD, and patient

Too Much of a Good Thing: Managing Immunotherapy Side Effects

Immunotherapy can backfire when a supercharged immune system attacks healthy cells, but researchers are hopeful for the future.

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

Pancreatic Cancer Patients with BRCA Mutation May Benefit from Targeted Drug

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

Daruka Mahadevan, MD, PhD, and Eric Weterings, PhD

Immunotherapy: Harnessing the Power of the Immune System

Designer antibodies, such as checkpoint inhibitors, have revolutionized cancer treatment.

News Stories

Immunotherapy can backfire when a supercharged immune system attacks healthy cells, but researchers are hopeful for the future.

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

The company targets accelerated diagnosis and treatment of cancer by providing optimal tissue samples for effective personalized medicine.